CF
HELP

Cantor Fitzgerald’s Helus Pharma Inc. Common Stock HELP Stock Holding History

Cantor Fitzgerald’s Portfolio HELP Stock Details HELP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,895
Closed -$145K – 729
2022
Q3 		$145K Buy
+7,895
New +$214K ﹤0.01% 621

Other funds holding HELP

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
IWP
IAG Wealth Partners Waukesha, Wisconsin $1.01B AUM 17.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Cantor Fitzgerald's HELP Position: Q4 2022 in Review

Cantor Fitzgerald sold out of Helus Pharma Inc. Common Stock (HELP) in Q4 2022, closing a stake of 7,895 shares — an estimated $145K sold.

Cantor Fitzgerald first reported a position in HELP in Q3 2022 and held it in 1 quarter. The position peaked at $145K in Q3 2022. 70 funds tracked by Wall St. Rank hold HELP as of Q4 2022.

  • Cantor Fitzgerald reported no remaining Helus Pharma Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Cantor Fitzgerald sold 7,895 Helus Pharma Inc. Common Stock shares in Q4 2022, an estimated $145K.
  • Cantor Fitzgerald first reported a position in Helus Pharma Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Cantor Fitzgerald's Helus Pharma Inc. Common Stock position peaked at $145K in Q3 2022.
  • 70 funds tracked by Wall St. Rank held Helus Pharma Inc. Common Stock as of Q4 2022.

Based on Cantor Fitzgerald's 13F filing for Q4 2022, filed 14 Feb 2023.